Asian Science Citation Index is committed to provide an authoritative, trusted and significant information by the coverage of the most important and influential journals to meet the needs of the global scientific community.  
ASCI Database
308-Lasani Town,
Sargodha Road,
Faisalabad, Pakistan
Fax: +92-41-8815544
Contact Via Web
Suggest a Journal
Articles by T. Begum
Total Records ( 2 ) for T. Begum
  A. Sarwar , M.S. Rahman , T.B. Huq , K. Biswas , M.I. Hussain , J.F. Chaity , T. Begum , Md. E. Haque , A. Islam and Mst. M. Begum
  Background and Objective: To compare the prevalence of acute vomiting between patients receiving cisplatin as monotherapy or cisplatin in a combination regimen. Materials and Methods: The study was conducted at Delta Hospital Dhaka on a total of 70 patients (44 male and 26 female). The patients received either cisplatin alone or cisplatin with the following chemotherapeutic agents-docetaxel and 5 fluorouracil, docetaxel, etoposide, doxorubicin and capecitabine. The study was conducted in patients receiving chemotherapy for a total of the first 3 cycles. The patients were told to record the number of episodes of vomiting they experienced during the first 24 h after chemotherapy at each cycle. All 70 patients received prechemotherapy antiemetics a combination of 5HT3 receptor antagonist (ondansetron or palanosetron) and dexamethasone prior to chemotherapy. Results: In patients receiving the combination chemotherapy of cisplatin+docetaxel+5 FU experienced the lowest incidence of acute vomiting and cisplatin+capecitabine receiving patients experienced highest incidence of acute vomiting. All the other combination therapy resulted in emesis comparatively similar to that of cisplatin. In all the regimens except for cisplatin+etoposide the percentage of patients experiencing acute vomiting reduced along with progressive cycles. Conclusion: When cisplatin is given in combination regimen except for the combination regimen of cisplatin+capecitabine there is no significant increase in emesis between patients receiving cisplatin alone or in combination therapy.
  M. Alauddin , T. Parvin and T. Begum
  The mechanism of clouding of nonionic surfactant and the effect of additives on the cloud point has been investigated. The cloud point temperature of Triton X-100 solutions in the concentration range 1-10% and the cloud point behavior of 4 and 10% Triton X-100 solutions in the presence of some aliphatic alcohols and alkanes of different concentrations have been studied. A sharp rise in cloud point of aqueous solutions of Triton X-100 occurs with increasing surfactant concentration beyond 4%. A small but significant decrease in cloud point is observed upon the addition of hexane, heptane, octane and decane to 4 and 10% Triton X-100 solutions. The alkanes of higher chain length are more effective in depressing the cloud point and the extent of depression follows the order: decane>octane>heptane>hexane. Lower alcohols enhance the cloud point while the higher alcohols including butoxyethanol depress the cloud point. The depression of cloud point of Triton X-100 solutions containing same amount of alcohols follows the order: decanol>octanol>heptanol>hexanol>butanol.
Copyright   |   Desclaimer   |    Privacy Policy   |   Browsers   |   Accessibility